Highlights of weekly biotech stock moves

Alimera Sciences Inc. (NASDAQ:ALIM) was up $0.56 (12%) to $5.05 last week after the U.K.'s NICE issued draft guidance recommending Iluvien fluocinolone acetonide intravitreal implant for chronic diabetic macular edema (DME) patients considered insufficiently responsive to available therapies and who have had their natural lens replaced with an intraocular lens.

The recommendation, which reverses final guidance issued in January, is contingent on Alimera providing Iluvien at an undisclosed discount under a patient access scheme...